U.S. Markets open in 3 hrs 38 mins

Incyte Corporation (INCY)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
133.56-4.71 (-3.41%)
At close: 4:00PM EDT
People also watch
VRTXBMRNALXNREGNSGEN
Full screen
Previous Close138.27
Open134.13
Bid131.00 x 100
Ask133.50 x 100
Day's Range132.88 - 136.97
52 Week Range75.52 - 153.15
Volume1,826,726
Avg. Volume1,718,173
Market Cap27.35B
Beta1.80
PE Ratio (TTM)-237.23
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com14 hours ago

    Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

    Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.

  • Eli Lilly Tumbles On Arthritis Drug Delay
    Investor's Business Daily14 hours ago

    Eli Lilly Tumbles On Arthritis Drug Delay

    A delay in getting its rheumatoid arthritis drug to market by at least 18 months sent Eli Lilly shares lower Tuesday.

  • Barrons.com18 hours ago

    Eli Lilly: What the Heck Just Happened?

    Eli Lilly (LLY) beat earnings forecasts today, but all anyone wants to talk about is a delayed filing for its the rheumatoid arthritis drug it's developing with Incyte (INCY). Eli Lilly reported an adjusted profit of $1.11, topping the Street consensus for $1.05, on sales of $5.82 billion, above expectations for $5.59 billion. Unfortunately, Eli Lilly and Incyte announced that their resubmission of a New Drug Application for their rheumatoid arthritis drug, baricitinib, would be delayed.